Updated July 2026 · 8 min read

Sulfonylurea Overdose for ICU Nurses 2026 — The Hypoglycemia That Keeps Coming Back

Part of the ICU Emergencies Hub — browse every related guide in one place.

A patient comes in confused and diaphoretic, the fingerstick reads 38, you push an amp of D50, and they wake up and look great. An hour later they are obtunded again. This is the signature of sulfonylurea overdose, and it is the reason these poisonings are dangerous out of proportion to how well the patient looks after the first correction. The drug keeps squeezing insulin out of the pancreas for many more hours than one dose of dextrose can cover, and the treatment that actually breaks the cycle is not more sugar — it is a medication that turns the pancreas off.

Why the hypoglycemia relapses

Sulfonylureas work by binding to a receptor on the pancreatic beta cell that closes potassium channels, which depolarizes the cell and drives it to secrete insulin. Crucially, this insulin release is not tied to how much glucose is actually in the blood — the drug forces secretion regardless. That is the whole problem in overdose: the pancreas keeps dumping insulin even as the blood sugar falls to dangerous levels, and it keeps doing so for as long as the drug is on the receptor. Because many of these agents are long-acting and are renally cleared, the effect outlasts a single dose of dextrose by many hours, and in patients with kidney impairment or advanced age it can persist for a day or more. This is why the deceptively reassuring pattern — correct, wake up, relapse — is so treacherous. The patient who looks perfect after an amp of D50 has not been treated; they have merely been reset, and the clock on the next crash is already running. A pediatric ingestion of even one or two tablets, or a therapeutic dose in a fasting elderly patient, can produce the same prolonged danger, so the amount does not have to be large.

Why dextrose alone is a trap — and octreotide is the answer

The instinct is to treat low sugar with sugar, and dextrose is absolutely the right first move for an acutely hypoglycemic, symptomatic patient. But there is a cruel feedback loop: giving glucose raises the blood sugar, which itself stimulates the drugged beta cell to release even more insulin, which drives the sugar back down. Chasing sulfonylurea hypoglycemia with dextrose boluses alone can therefore produce a sawtooth of crashes that never truly resolves, and pushing concentrated dextrose repeatedly through a peripheral line risks vein damage and rebound. Octreotide, a somatostatin analog, breaks the loop at the source by directly suppressing insulin secretion from the beta cell. Once octreotide is on board, glucose tends to stabilize and the recurrent crashes stop, often dramatically reducing the amount of dextrose required. The classic teaching is that octreotide is the definitive treatment for sulfonylurea-induced hypoglycemia, with dextrose as the acute rescue and octreotide as the therapy that actually holds the line.

Bedside priorities

The nursing role in a sulfonylurea overdose is built around one principle: assume the hypoglycemia will come back and monitor as if it will. First, treat symptomatic lows promptly with dextrose and reassess the fingerstick quickly afterward — and then keep checking. Frequent bedside glucose monitoring (often every 30–60 minutes early, then spacing out only as stability is proven) is the backbone of care, because the next crash can arrive quietly in a patient who seemed fine. Anticipate and expedite the octreotide order for recurrent hypoglycemia, and understand that its purpose is to stop the relapses rather than to raise a single number. Maintain reliable IV access and be ready to run a dextrose infusion rather than relying on repeated boluses. For a patient with an intact airway and swallow, offering complex oral carbohydrate can help sustain glucose between checks. Watch the neuro status closely — confusion, slurred speech, sweating, tremor, or a drop in level of consciousness may all signal a recurrence — and remember that beta-blockers or sedation can blunt the usual adrenergic warning signs. Critically, these patients require admission and an extended observation period, typically well beyond the first correction and often overnight, so guard against premature discharge pressure. If the ingestion was intentional, ensure the poisoning workup and mental-health evaluation move forward, and loop in the poison center, who guide dosing and duration.

The nursing bottom line

Sulfonylurea overdose is prolonged, recurrent hypoglycemia caused by a pancreas that has been forced to keep releasing insulin for hours to days, and its danger lies in how well the patient looks after the first correction. Dextrose is the right rescue but a false finish line, because the sugar it delivers stimulates still more insulin; the treatment that actually ends the cycle is octreotide, which shuts insulin secretion off at the beta cell. The nurse who keeps checking the glucose long after the patient wakes up, who anticipates octreotide for the relapses, and who resists the pull to discharge early is the one who prevents the quiet, delayed crash that makes these poisonings lethal. In sulfonylurea overdose, the treatment is not sugar — it is patience, monitoring, and turning the pancreas off.

Related: Beta-blocker overdose · Calcium channel blocker overdose · Digoxin toxicity · DKA vs. HHS

Educational content for licensed clinicians. Always follow your facility's protocol and provider orders. Not medical advice.